Recent chatter on X about IO Biotech (IOBT) has been heating up, largely driven by discussions around the company's ongoing Phase 3 clinical trials and financial health. Several users have pointed out the high stakes of the trial results, noting that a failure could lead to a sharp decline in stock price. The conversation also touches on the firm's rapid cash burn, raising concerns about long-term sustainability.
Additionally, there’s a mix of optimism and caution in the dialogue, with some highlighting IOBT as a potential opportunity despite the risks. A few have noted recent analyst upgrades, such as a raised price target from a major financial institution, as a positive signal. The tension between clinical potential and financial pressures keeps the discussion dynamic and engaging.
Note: This discussion summary was generated from an AI condensation of post data.
IO Biotech Insider Trading Activity
IO Biotech insiders have traded $IOBT stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IOBT stock by insiders over the last 6 months:
- HEIDI HUNTER purchased 15,000 shares for an estimated $20,884
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
IO Biotech Hedge Fund Activity
We have seen 5 institutional investors add shares of IO Biotech stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC removed 224,949 shares (-83.2%) from their portfolio in Q1 2025, for an estimated $245,194
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 99,000 shares (-56.9%) from their portfolio in Q1 2025, for an estimated $107,910
- MORGAN STANLEY removed 69,714 shares (-8.1%) from their portfolio in Q1 2025, for an estimated $75,988
- DAUNTLESS INVESTMENT GROUP, LLC removed 66,200 shares (-8.9%) from their portfolio in Q1 2025, for an estimated $72,158
- ROYAL BANK OF CANADA removed 60,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $65,400
- LANDSCAPE CAPITAL MANAGEMENT, L.L.C. removed 41,962 shares (-9.5%) from their portfolio in Q1 2025, for an estimated $45,738
- UBS GROUP AG removed 34,675 shares (-73.7%) from their portfolio in Q1 2025, for an estimated $37,795
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
IO Biotech Analyst Ratings
Wall Street analysts have issued reports on $IOBT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 04/01/2025
To track analyst ratings and price targets for IO Biotech, check out Quiver Quantitative's $IOBT forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
